KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Equity Ratio: 2009-2025

Historic Equity Ratio for Novavax (NVAX) over the last 15 years, with Sep 2025 value amounting to -0.13.

  • Novavax's Equity Ratio rose 56.81% to -0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -0.13, marking a year-over-year increase of 56.81%. This contributed to the annual value of -0.40 for FY2024, which is 0.24% down from last year.
  • According to the latest figures from Q3 2025, Novavax's Equity Ratio is -0.13, which was down 571.69% from 0.03 recorded in Q2 2025.
  • In the past 5 years, Novavax's Equity Ratio ranged from a high of 0.40 in Q1 2021 and a low of -0.64 during Q1 2024.
  • In the last 3 years, Novavax's Equity Ratio had a median value of -0.40 in 2023 and averaged -0.33.
  • Per our database at Business Quant, Novavax's Equity Ratio spiked by 645.23% in 2021 and then crashed by 2,619.33% in 2023.
  • Quarterly analysis of 5 years shows Novavax's Equity Ratio stood at -0.14 in 2021, then plummeted by 105.69% to -0.28 in 2022, then crashed by 42.08% to -0.40 in 2023, then dropped by 0.24% to -0.40 in 2024, then soared by 56.81% to -0.13 in 2025.
  • Its Equity Ratio stands at -0.13 for Q3 2025, versus 0.03 for Q2 2025 and -0.06 for Q1 2025.